U.S. Exempts U.K. Pharmaceuticals from Section 232 Tariffs
The U.S. and U.K. reach a pharmaceutical trade agreement. U.K. drugs and medical technology are exempt from U.S. tariffs, while the U.K. increases payments for new medicines. The deal strengthens supply chains, encourages investment, and supports fair pricing for American patients.